FDA Approved: SURVANTA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for SURVANTA (beractant) submitted by AbbVie Inc., approving changes to the product's labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Respiratory Distress Syndrome

Drugs mentioned

• SURVANTA (beractant)

Snippet

SUPPL AP for SURVANTA (BERACTANT)